How often do I need cervical screening in Australia?

Under the National Cervical Screening Program (NCSP), cervical screening is recommended every five years for anyone with a cervix aged 25 to 74. This is longer than the previous two-to-three-year Pap smear interval because primary HPV testing is more sensitive — it detects the virus that causes cervical cancer, not just abnormal cells, giving a longer reassurance window when the result is negative. If HPV is detected on your screening test, your GP will advise on the next step, which may be a repeat test in 12 months or referral to a specialist. Symptoms such as irregular bleeding should prompt a diagnostic appointment regardless of when your last screening was.

What is self-collection and is it as accurate?

Self-collection means collecting a vaginal swab yourself, in private — without a speculum examination. The swab is then tested for HPV. Research shows self-collection is equally accurate to clinician-collected swabs for detecting HPV. It has been available to all eligible Australians since 1 July 2022, not only those who were previously underscreened. Self-collection is a valid option for anyone who finds speculum examinations uncomfortable, distressing, or difficult due to cultural, physical, or trauma-related reasons. If HPV is detected on a self-collected swab, a clinician-collected specimen is then required so that reflex liquid-based cytology can be performed to characterise the result.

What happens if my HPV test comes back positive?

A positive HPV result means the human papillomavirus was detected — not that you have or will develop cervical cancer. Most HPV infections clear on their own within one to two years. What happens next depends on which HPV types are present. If HPV types 16 or 18 are detected — the highest-risk types — you will be referred directly for colposcopy. If other HPV types are detected with normal or low-grade cytology, a repeat HPV test in 12 months is recommended. If the HPV persists at the 12-month repeat, colposcopy is then arranged. Colposcopy is a specialist examination of the cervix under magnification, with biopsy if needed, and does not necessarily mean cancer.

Do I need cervical screening after a hysterectomy?

This depends on the type of hysterectomy and why it was performed. A total hysterectomy — in which the cervix is completely removed — generally means cervical screening is no longer needed, provided there was no prior high-grade cervical abnormality or cervical cancer. If you had a subtotal or partial hysterectomy in which the cervix was left in place, regular cervical screening should continue. If you had a hysterectomy because of a high-grade cervical condition or cervical cancer, ongoing surveillance is usually recommended — your specialist will advise. Always tell your GP what kind of hysterectomy you had, and the reason, so your screening needs can be assessed accurately.

Who is most at risk of cervical cancer not being caught early?

The groups most likely to miss cervical cancer are those who have never been screened or are significantly overdue. In Australia, this includes Aboriginal and Torres Strait Islander women — who have cervical cancer rates approximately double the national average — recent immigrants from countries without organised screening programs, women who find speculum examinations traumatic or distressing, and women in remote or rural areas with limited access to health services. Self-collection has substantially improved access for many of these groups since 2022. A GP can now offer self-collection in the clinic as an alternative to speculum examination, removing a major barrier for many underscreened women.

Cervical cancer screening and HPV

Cervical screening and HPV in Australia: NCSP, self-collection, Gardasil 9

By Dr HB Lo, FACRRM Reviewed 5 June 2026 8 min read

Australia's NCSP switched from Pap smear to primary HPV testing in December 2017 — now a five-yearly HPV test for people with a cervix aged 25 to 74. Self-collection via vaginal swab (available since 1 July 2022) is equivalent to clinician-collected testing.

Australia is on track to eliminate cervical cancer as a public health problem (fewer than 4/100,000) by approximately 2035, driven by Gardasil 9 vaccination and the sensitive HPV-based screening program.

Gardasil 9 is a single dose for eligible people up to age 25 under the NIP. Vaccinated people still require regular cervical screening.

Australia is on track to be among the first countries in the world to eliminate cervical cancer as a public health problem — defined as fewer than four cases per 100,000 — by approximately 2035. This trajectory is driven by two parallel strategies: high HPV vaccination rates since 2007, and the transition in December 2017 from the Pap smear to a more sensitive National Cervical Screening Program (NCSP) built on primary HPV testing.

Currently, approximately 900 cervical cancers and 250 deaths occur in Australia each year. Aboriginal and Torres Strait Islander women experience approximately twice the incidence and mortality of non-Indigenous women — a gap that targeted programs, improved screening access, and the expansion of self-collection are designed to close.

The GP’s role in the NCSP is to ensure eligible patients are recalled, offer self-collection as a genuine alternative, interpret results and act on the result pathway, opportunistically offer HPV vaccination to eligible young people, and manage common HPV-related presentations such as genital warts.

A. Core clinical — the AU general-practice framework

Who is eligible and how often

Primary HPV testing is recommended every five years for anyone with a cervix aged 25 to 74 years — whether or not they have been HPV-vaccinated. The five-year interval is safe because a negative HPV test provides a longer window of reassurance than a normal Pap smear did: the virus that causes cervical cancer is detected before abnormal cells develop, and an absent virus means very low cancer risk over the following five years.

Clinician-collected versus self-collected screening

Clinician-collected specimen: A liquid-based cytology sample is collected via speculum examination. If HPV is detected, reflex cytology is automatically performed on the same specimen.

Self-collected specimen: A vaginal swab, taken in private by the patient without speculum examination. Available to all eligible people since 1 July 2022. Research demonstrates equivalent sensitivity for HPV detection. Self-collection removes major access barriers for people affected by trauma, cultural concerns, disability, or embarrassment. Important difference: if HPV is detected on a self-collected swab, a follow-up clinician-collected specimen is required to perform reflex cytology and characterise the result — this should be clearly explained when offering self-collection.

Result pathway

Per the NCSP and Cancer Council Australia clinical guidelines:

Result	Recommended action
HPV not detected	Routine 5-yearly recall
HPV detected — non-16/18 + normal or LSIL cytology	Repeat HPV test in 12 months
HPV detected — non-16/18 + persistent at 12-month repeat	Refer to colposcopy
HPV 16 or 18 detected (any cytology)	Refer to colposcopy
High-grade cytology (HSIL, glandular abnormality)	Refer to colposcopy
Self-collection: HPV positive	Follow-up clinician-collected specimen, then per pathway above
Symptomatic patient	Diagnostic workup regardless of screening interval

HPV vaccination

Gardasil 9 covers nine HPV types: high-risk oncogenic types 16, 18, 31, 33, 45, 52, 58 (responsible for most cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers), plus low-risk types 6 and 11 (responsible for 90% of genital warts).

Since 2023, ATAGI recommends a single dose for adolescents aged 12 to 13 — with equivalent immunogenicity shown to the previous two-dose schedule in people aged up to 25. The National Immunisation Program funds:

School-based program age 12 to 13 (Year 7)
Catch-up for people up to age 25 free through general practice or immunisation clinics
Extended NIP eligibility: MSM aged ≤26 for catch-up; immunocompromised individuals (HIV, transplant, biologic therapy, haematological malignancy) — three doses for this group; extended coverage for ATSI people

HPV-vaccinated people still need regular cervical screening — Gardasil 9 does not protect against all HPV types, and the full vaccination era cohort has not yet reached the screening entry age of 25.

B. Evidence appraisal — the science behind the NCSP

Primary HPV testing vs Pap smear

The shift to primary HPV testing in 2017 was evidence-led. HPV testing is more sensitive than cervical cytology for detecting CIN 2 and CIN 3 lesions — meaning more high-grade precancers are found per round of screening. The test is also more specific: a negative HPV test provides higher reassurance than a normal Pap, justifying the extended five-year interval. Australian and international RCT evidence consistently supports HPV primary screening as superior for preventing invasive cervical cancer at a population level.

Self-collection — evidence for equivalence

Meta-analyses and Australian implementation data confirm that vaginal self-collection using a swab tested for HPV DNA is statistically equivalent to clinician-collected liquid-based cytology for HPV detection. Self-collection substantially improved participation among previously underscreened women in Australian pilot programs. The important procedural caveat — that HPV-positive self-collection requires follow-up clinician collection for reflex cytology — is manageable in general practice and does not negate the substantial access benefits.

Single-dose Gardasil 9

The WHO Strategic Advisory Group of Experts (SAGE) on Immunisation concluded in 2022 that one dose of HPV vaccine in adolescents aged 9 to 20 achieves comparable immunogenicity to a two-dose schedule. ATAGI adopted this recommendation for the Australian NIP in 2023. Long-term durability data are accumulating and are so far reassuring. Immunocompromised individuals continue to require three doses because immune response to a single dose is attenuated.

Australia’s elimination trajectory

Modelling published in The Lancet Oncology projects Australia will reach the WHO elimination threshold (fewer than 4 per 100,000 per year) by approximately 2028 to 2035, with earlier elimination possible if vaccination and screening participation continue to improve. Closing the gap for ATSI women is a specific target — cultural safety initiatives, community-based outreach, and self-collection access in remote areas are the key levers.

C. Symptomatic presentations and diagnostic workup

A symptomatic patient — regardless of when their last screening was — needs diagnostic evaluation, not a deferred or routine screening test.

Symptoms that require diagnostic assessment:

Intermenstrual bleeding (bleeding between periods)
Postcoital bleeding (bleeding after sex)
Postmenopausal bleeding — primarily raises concern for endometrial cancer but cervical cancer must also be excluded; see your GP promptly
Persistent unusual vaginal discharge, particularly watery or blood-stained
Pelvic pain that is new or unexplained
Visible cervical lesion on any examination

The diagnostic pathway includes HPV test plus liquid-based cytology, colposcopy with directed biopsy, and referral for multidisciplinary gynaecology-oncology assessment if cancer is confirmed.

Colposcopy (gynaecologist-performed, MBS item 35508) provides magnified visualisation of the transformation zone. LSIL/CIN 1 may be observed and repeated. HSIL/CIN 2 and CIN 3 are treated with LLETZ (large loop excision of the transformation zone) — an outpatient electrosurgical excision under local anaesthesia. Test of cure follow-up at six to twelve months post-LLETZ checks for clearance.

Genital warts (HPV types 6 and 11): topical podophyllotoxin self-applied at home, imiquimod cream, or in-clinic cryotherapy — both podophyllotoxin and imiquimod are PBS Authority items for anogenital warts. Refractory or extensive disease warrants dermatology, gynaecology, or sexual health specialist input.

D. Australian operations

MBS items in general practice:

Cervical screening test (HPV): item 73070 range — bulk-billed under the NCSP; covers both clinician-collected and self-collected testing
Colposcopy: item 35508 — specialist gynaecology
Standard consultations: items 3, 23, 36, 44
ATSI Health Assessment: item 715 — structured opportunity for screening status review and self-collection offer
45 to 49 Health Assessment: item 701; 75+ Health Assessment: item 705 — cervical screening status check at each
Practice nurse vaccination: item 10987 — for HPV vaccine administration
Mental Health Care Plan: items 2715, 2717 — for trauma-related psychological barriers to clinician-collected screening

NCSP register: Results are notified to the NCSP register, which generates recall reminders. Practices should have an active recall system to identify patients overdue for screening. The NCSP register is separate from practice software recalls — confirm your practice is connected.

NIP — Gardasil 9: Free for eligible recipients via school-based programs or general practice. Private cost for those outside NIP eligibility: approximately $200 to $250 for one dose.

E. Special populations

Immunocompromised individuals (HIV, solid organ transplant, biologic therapy for IBD or rheumatological conditions, haematological malignancy): Earlier initiation of screening, more frequent intervals — consult specialist guidelines. Three doses of Gardasil 9 are required, not one. HPV infection is less likely to clear spontaneously; CIN progression is accelerated.

Trans and non-binary people with a cervix — eligible for NCSP if aged 25 to 74 and the cervix is present. The NCSP now uses gender-inclusive language. Self-collection may be particularly valuable for trans men for whom speculum examination is distressing. Sensitive, affirming communication and using preferred terms are important aspects of inclusive practice.

Post-hysterectomy — total hysterectomy (cervix removed) generally means screening ceases, unless there was prior high-grade CIN or cervical cancer. Subtotal hysterectomy (cervix retained) — continue screening. Document the specific surgical procedure and indication in the medical record.

Recent immigrants and refugees — women from countries without organised screening programs may never have been screened or may have received Pap smears rather than HPV testing. Offer catch-up screening and HPV vaccination if eligible. Language access services support informed consent for screening.

ATSI Australians — cervical cancer incidence approximately twice the national rate. Targeted programs and community-controlled health organisations improve access. Self-collection in remote areas is available and effective.

When to escalate

Refer urgently (within days to two weeks) for:

Suspected cervical cancer — visible lesion, HSIL cytology with clinical concern, glandular abnormality on cytology — urgent gynaecology-oncology referral
Postmenopausal bleeding — assess for endometrial and cervical cancer concurrently; transvaginal ultrasound plus biopsy

Refer routinely for colposcopy:

HPV 16 or 18 detected on any screen
Persistent HPV (any type) at the 12-month repeat test
HSIL on reflex cytology at any HPV-positive screen
Glandular abnormality — warrants urgent colposcopy plus endocervical assessment

What this article is and is not

This is general health information based on the National Cervical Screening Program, Australian Immunisation Handbook, Cancer Council Australia guidelines, and RANZCOG. It is not personal medical advice. Symptoms such as irregular bleeding should prompt prompt review with your own GP regardless of recent screening status.

For Australian consumer resources: HealthDirect — Cervical screening test, NCSP self-collection information, Cancer Council, Better Health Channel.

Sources cited

Frequently asked questions

How often do I need cervical screening in Australia?

Under the National Cervical Screening Program (NCSP), cervical screening is recommended every five years for anyone with a cervix aged 25 to 74. This is longer than the previous two-to-three-year Pap smear interval because primary HPV testing is more sensitive — it detects the virus that causes cervical cancer, not just abnormal cells, giving a longer reassurance window when the result is negative. If HPV is detected on your screening test, your GP will advise on the next step, which may be a repeat test in 12 months or referral to a specialist. Symptoms such as irregular bleeding should prompt a diagnostic appointment regardless of when your last screening was.
What is self-collection and is it as accurate?

Self-collection means collecting a vaginal swab yourself, in private — without a speculum examination. The swab is then tested for HPV. Research shows self-collection is equally accurate to clinician-collected swabs for detecting HPV. It has been available to all eligible Australians since 1 July 2022, not only those who were previously underscreened. Self-collection is a valid option for anyone who finds speculum examinations uncomfortable, distressing, or difficult due to cultural, physical, or trauma-related reasons. If HPV is detected on a self-collected swab, a clinician-collected specimen is then required so that reflex liquid-based cytology can be performed to characterise the result.
Is the HPV vaccine still needed if I have had all my Pap smears?

Yes — the HPV vaccine protects against future infection with HPV types not yet acquired, and is valuable even if someone has been previously screened or has had a prior HPV infection. Gardasil 9 protects against nine HPV types responsible for most cervical, vulvar, vaginal, anal, and oropharyngeal cancers, plus genital warts. Since 2023, ATAGI recommends a single dose for people aged up to 25. The vaccine is funded free under the National Immunisation Program for eligible adolescents aged 12 to 13 through school-based programs, with catch-up to age 25. People who are vaccinated still need regular cervical screening, as Gardasil 9 does not cover all oncogenic HPV types.
What happens if my HPV test comes back positive?

A positive HPV result means the human papillomavirus was detected — not that you have or will develop cervical cancer. Most HPV infections clear on their own within one to two years. What happens next depends on which HPV types are present. If HPV types 16 or 18 are detected — the highest-risk types — you will be referred directly for colposcopy. If other HPV types are detected with normal or low-grade cytology, a repeat HPV test in 12 months is recommended. If the HPV persists at the 12-month repeat, colposcopy is then arranged. Colposcopy is a specialist examination of the cervix under magnification, with biopsy if needed, and does not necessarily mean cancer.
Do I need cervical screening after a hysterectomy?

This depends on the type of hysterectomy and why it was performed. A total hysterectomy — in which the cervix is completely removed — generally means cervical screening is no longer needed, provided there was no prior high-grade cervical abnormality or cervical cancer. If you had a subtotal or partial hysterectomy in which the cervix was left in place, regular cervical screening should continue. If you had a hysterectomy because of a high-grade cervical condition or cervical cancer, ongoing surveillance is usually recommended — your specialist will advise. Always tell your GP what kind of hysterectomy you had, and the reason, so your screening needs can be assessed accurately.
Who is most at risk of cervical cancer not being caught early?

The groups most likely to miss cervical cancer are those who have never been screened or are significantly overdue. In Australia, this includes Aboriginal and Torres Strait Islander women — who have cervical cancer rates approximately double the national average — recent immigrants from countries without organised screening programs, women who find speculum examinations traumatic or distressing, and women in remote or rural areas with limited access to health services. Self-collection has substantially improved access for many of these groups since 2022. A GP can now offer self-collection in the clinic as an alternative to speculum examination, removing a major barrier for many underscreened women.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.

T1 AU primary 10 sources